Discovering The Potential of AATF as A Cancer Biomarker (G26574)

Target Name: AATF

NCBI ID: G26574

AATF

Discovering The Potential of AATF as A Cancer Biomarker

Apoptosis-antagonizing transcription factor (AATF) is a protein that plays a crucial role in cell survival and has been linked to a variety of diseases, including cancer. Despite its importance, little is known about AATF, making it a promising drug target or biomarker. In this article, we will explore the biology of AATF, its potential as a drug target, and its potential as a biomarker for various diseases.

Biochemistry and Function

AATF is a member of the AP-1 gene family, which encodes transcription factors that regulate gene expression. AATF is characterized by a N-terminal transcription factor domain and a C-terminal domain that contains a leucine-rich repeat (LRR) and a domain-swapped fragment (DSP). The LRR and DSP domains give AATF its unique structure and function.

The LRR domain is a N-terminal region that contains a leucine-rich repeat, which is a common motif in transcription factors. The LRR domain functions as a binding site for DNA, allowing AATF to interact with its target genes. The DSP domain is a C-terminal region that contains a domain-swapped fragment and is responsible for the interaction between AATF and its co-regulated genes.

AATF is involved in a variety of cellular processes, including cell growth, apoptosis, and transcriptional regulation. One of its well-documented functions is its role in cell apoptosis. AATF has been shown to promote apoptosis in various cell types, including cancer cells. This process is mediated by AATF-mediated alterations in cellular signaling pathways, including the production of reactive oxygen species (ROS) and the inhibition of antioxidant enzymes.

In addition to its role in cell apoptosis, AATF has also been shown to promote cell cycle progression. This process is mediated by AATF-mediated alterations in the expression of genes involved in the cell cycle, including the inhibition of the tumor suppressor protein p53.

Potential Drug Target

AATF's unique structure and function make it an attractive drug target. Given its role in cell apoptosis and its potential to promote cell cycle progression, AATF could be a useful target for cancer treatments. Several studies have shown that inhibiting AATF can lead to the inhibition of various cellular processes that are associated with cancer growth, including the production of ROS, the inhibition of p53, and the promotion of cell cycle progression.

AATF has also been shown to interact with several small molecules, including drugs that are currently being used to treat cancer. For example, inhibitors of the AATF have been shown to be effective in inhibiting the growth of various cancer cell types, including breast, ovarian, and colorectal cancer.

Biomarker Potential

AATF's involvement in cell apoptosis and its potential as a drug target make it an attractive biomarker for various diseases. AATF has been shown to be involved in a variety of cellular processes, including cell apoptosis, cell cycle progression, and transcriptional regulation. This makes it a potential biomarker for a variety of diseases, including cancer.

One of the challenges in using AATF as a biomarker is its limited expression in certain tissues, which can make it difficult to study its effects in these tissues. Additionally, the complexity of AATF's function in cellular processes makes it difficult to predict its effects as a biomarker. However, given its potential as a drug target and its involvement in cell apoptosis, AATF is a promising biomarker for

Protein Name: Apoptosis Antagonizing Transcription Factor

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797). May function as a general inhibitor of the histone deacetylase HDAC1. Binding to the pocket region of RB1 may displace HDAC1 from RB1/E2F complexes, leading to activation of E2F target genes and cell cycle progression. Conversely, displacement of HDAC1 from SP1 bound to the CDKN1A promoter leads to increased expression of this CDK inhibitor and blocks cell cycle progression. Also antagonizes PAWR mediated induction of aberrant amyloid peptide production in Alzheimer disease (presenile and senile dementia), although the molecular basis for this phenomenon has not been described to date

The "AATF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AATF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets